Dyslipidemia: New Challenges and Emerging Options in Lowering CVD Risk- Activity 3: Incorporating PCSK9 Inhibitors Into the Management of Patients With Dyslipidemia

New 3-part online continuing education eCourse exploring the changing landscape of dyslipidemia management.  Experts in lipidology examine treatment guidelines, strategies for CV risk reduction, and the value of collaborative care for patients.



Program Description

Reduction of low-density lipoprotein cholesterol (LDL-C) is widely recognized as an effective intervention for reducing cardiovascular risk, and robust evidence supports aggressive use of statins to lower LDL-C. However, some patients cannot achieve adequate reduction in their LDL-C levels with statins, even with the addition of other classes of antidyslipidemic agents. This interactive 3-part CME/CPE eCourse convenes 3 experts in lipidology to discuss current options and emerging therapies for lowering LDL-C. In Activity 3, the focus is on 2 newly approved PCSK9 inhibitors, alirocumab and evolocumab. These agents reduce LDL-C levels dramatically—often to levels never achieved before—and, combined with statins, the effect is additive.

Click her to launch this activity

No votes yet
Activity Classification

This activity is instructional only and may not be taken for credit.

Content Domain
This activity falls under the following content domain(s):

Learning Objectives
This activity teaches to the following learning objective(s):

  1. Consider a collaborative care practice model to foster adherence to lipid-lowering medications through monitoring and patient engagement
  2. Identify appropriate patients with dyslipidemia who would benefit from alternative treatment strategies, such as PCSK9 inhibition

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service